Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/12/2667 |
| _version_ | 1797454975622709248 |
|---|---|
| author | Yasmin Marra Fawziah Lalji |
| author_facet | Yasmin Marra Fawziah Lalji |
| author_sort | Yasmin Marra |
| collection | DOAJ |
| description | Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively. Safety data from the effectiveness studies show similar results to the clinical trials with mostly local injection-site reactions and mild systemic reactions seen with both vaccines, although in larger proportions with the recombinant vaccine. Rare adverse events, occurring less than 1% of the time, have been seen with both vaccine types and include disseminated herpes zoster with the live zoster vaccine and Guillain–Barré syndrome with the recombinant vaccine. The wider use of preventative measures with vaccines will reduce the herpes zoster burden of illness seen in older adults. |
| first_indexed | 2024-03-09T15:44:54Z |
| format | Article |
| id | doaj.art-8810d98bb51846428797ccea93e66d8d |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T15:44:54Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-8810d98bb51846428797ccea93e66d8d2023-11-24T18:37:30ZengMDPI AGViruses1999-49152022-11-011412266710.3390/v14122667Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster VaccinesYasmin Marra0Fawziah Lalji1Faculty of Arts and Sciences, Queen’s University, Kingston, ON K7L 3N6, CanadaFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, CanadaInfection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively. Safety data from the effectiveness studies show similar results to the clinical trials with mostly local injection-site reactions and mild systemic reactions seen with both vaccines, although in larger proportions with the recombinant vaccine. Rare adverse events, occurring less than 1% of the time, have been seen with both vaccine types and include disseminated herpes zoster with the live zoster vaccine and Guillain–Barré syndrome with the recombinant vaccine. The wider use of preventative measures with vaccines will reduce the herpes zoster burden of illness seen in older adults.https://www.mdpi.com/1999-4915/14/12/2667herpes zostershinglesvaccine effectivenesszoster vaccinelive attenuated Oka varicella zoster vaccinerecombinant zoster vaccine |
| spellingShingle | Yasmin Marra Fawziah Lalji Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines Viruses herpes zoster shingles vaccine effectiveness zoster vaccine live attenuated Oka varicella zoster vaccine recombinant zoster vaccine |
| title | Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines |
| title_full | Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines |
| title_fullStr | Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines |
| title_full_unstemmed | Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines |
| title_short | Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines |
| title_sort | prevention of herpes zoster a focus on the effectiveness and safety of herpes zoster vaccines |
| topic | herpes zoster shingles vaccine effectiveness zoster vaccine live attenuated Oka varicella zoster vaccine recombinant zoster vaccine |
| url | https://www.mdpi.com/1999-4915/14/12/2667 |
| work_keys_str_mv | AT yasminmarra preventionofherpeszosterafocusontheeffectivenessandsafetyofherpeszostervaccines AT fawziahlalji preventionofherpeszosterafocusontheeffectivenessandsafetyofherpeszostervaccines |